Albert Bourla, President and CEO of Pfizer, speaks at the Wall Street Journal’s Future of Everything Festival in New York, in the United States, May 22, 2024.
Andrew Kelly | Reuters
Pfizer The CEO Albert Bourla said on Tuesday that uncertainty around the planned pharmaceutical rates of President Donald Trump dissuades the company from investing more in American manufacturing and development and development.
Bourla’s remarks on the call for profits from the first quarter of the company came in response to a question on what Pfizer wants to see tariff negotiations that would push the company to increase investments in the United States, it comes while drug manufacturers accumulate Trump’s levies from imported pharmaceutical products in the country – its administration offer to stimulate domestic manufacturing.
“If I know there will be no prices … then there are huge investments that can occur in this country, both in R&D and in manufacturing,” said Bourla during the call, adding that the company also hopes “certainty”.
“In the periods of uncertainty, everyone controls their cost as we do, then is very frugal with their investment, as we do, so that we are ready to give. This is what I want to see,” said Bourla.
Bourla noted that the fiscal environment, which had already pushed manufacturing abroad, “considerably changed now” with the creation of a minimum world tax of around 15%. He said that a quarter of work had not necessarily made the United States more attractive, saying “it is not as good” to invest here without additional incentives or clarity around prices.
“NOW [Trump] I am sure – and I know because I told him about it – that he would even like to see a reduction in the current tax regime, in particular for locally produced goods, “said Bourla, the addition of a new decrease would be a strong incitement for manufacturing in the United States
Unlike other companies with an evolving commercial policy, Pfizer has not revised its annual prospects on Tuesday. However, the company noted in its profits that the directives “currently include any potential impact linked to future prices and changes in commercial policy, which we are not able to foresee at the moment”.
But when the results were called on Tuesday, Pfizer leaders said the directives reflected $ 150 million in existing Trump prices.
“Included in our advice which we have not really talked about, there are prices in place today,” said the financial director of the Pfizer Dave Denton on the call.
“We are considering this in our orientation range and we continue at the trend at the upper end of our orientation range, even with these costs to be engaged this year,” he said.